Statistics from Altmetric.com
Juvenile dermatomyositis (JDM) is a rare autoimmune disorder, affecting mainly muscles and skin. The mainstay of treatment is high dose corticosteroids, combined with other immunosuppressive drugs.1 In about 30% of patients, the disease cannot be controlled despite multiple treatment interventions. Autologous stem cell transplantation (aSCT) has been reported as a last resort treatment in refractory patients with autoimmune diseases.2 The main hypothesis for the underlying immunological mechanism is that aSCT resets the immune system and restores immune tolerance following profound lymphodepletion and immune suppression.3
Here, we report three patients with refractory JDM that received aSCT (Clinical information, table 1). A short-term follow-up with detailed clinical information (including imaging before and after aSCT, and immune reconstitution after aSCT) of two patients describing complete remission was reported previously.4 The current follow-up of these patients is more than 5 years showing sustained remission. A third patient (#3) has a follow-up of nearly 3 years. Indication of aSCT for patient 3 was refractory muscle and skin inflammation comparable to the other two patients. Whole body MRI prior to aSCT confirmed active myositis. As muscle tests improved substantially after aSCT, MRI was not repeated post aSCT in this patient. Immune reconstitution was similar to those published.4 In patient 3 myositis is controlled and the patient is without systemic treatment at the time of publication. However, skin disease persists including calcinosis and contractures. Interestingly, autoantibody levels decreased in those patients with excellent response to aSCT (patients 1 and 2), but remained stable for patient 3 (table 1).
We have recently reported a typical proinflammatory protein plasma profile in patients with active JDM with three markers being highly correlated to disease activity: CXCL10, TNFR2 and Galectin-9.5 We measured these proteins before and at different time points after aSCT to determine kinetics and correlation to disease activity in the context of this intervention. Values of creatine kinase were not elevated in the weeks before aSCT and did not change after, indicating low correlation with actual disease activity. CXCL10, TNFR2 and Galectin-9 were elevated in the patients prior to the conditioning regimen, irrespective of maintenance treatment (figure 1A). After aSCT, these three markers decreased over time in patients 1 and 2 with the most pronounced reduction in levels of Galectin-9 and CXCL10. These levels remained low, even after full reconstitution of the immune system. In parallel, clinical scores improved over time as shown in figure 1B. Pre-existent severe calcinosis disappeared completely in patient 2 after aSCT4 but is still persisting in patient 3. Importantly, only in this patient, CXCL10 and Galectin-9 levels remained elevated after aSCT.
In contrast to TNFR2, CXCL-10 and Galectin-9 are produced by immune and non-immune cells under inflammatory conditions.6–9 As circulating immune cells are largely depleted during aSCT, our data suggest that CXCL10 and Galectin-9 are mainly produced by tissue cells or tissue infiltrating cells. Therefore, even during profound immunosuppression these markers may reveal ongoing disease activity in the tissues. This is also supported by the observation that CXCL10 and Galectin-9 levels dropped very gradually following aSCT in patients 1 and 2 and mirrored clinical disease improvement.
In conclusion these data demonstrate that aSCT can induce prolonged drug-free disease remission in refractory patients with JDM with regards to the myositis. Furthermore, we show that the proinflammatory signature as measured by TNFR2, CXCL-10 and Galectin-9 leads to a differentiated response after aSCT, with a marked decrease in the two patients with inactive disease but persistent elevation in a patient with skin involvement. Further studies are needed to determine the immunopathogenic role of these proteins in JDM.
The patients in this study gave informed consent to publication of the data. The authors thank Iris Haugg, Dr Julia Thomas and Dr Sandra Hansmann for providing clinical data and laboratory results.
FBE, EMD, AvR-K and FvW contributed equally.
Contributors Substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data; drafting the work or revising it critically for important intellectual content; final approval of the version published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: FBE, EMD, FvW, AvR-K, NW, BP, PvdT, JK-D.
Funding Ettore e Valeria Rossi Foundation; Bas Foundation, The Netherlands; ZonMw Veni grant from the Netherlands Organisation of Scientific Research (NWO); ZonMw AGIKO grant from the NWO; Reumafonds, the Netherlands.
Competing interests FBE is supported by Swiss Grants (The foundation of Ettore e Valeria Bossi). FBE is supported by the patient's society (Bas Stichting). FvW is supported by a ZonMw Veni grant from the Netherlands Organisation of Scientific Research (NWO). EMD is supported by a ZonMw AGIKO grant from the NWO. NW and BP are supported by the Reumafonds.
Ethics approval Netherlands, CCMO: NL34124.041.10.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.